GURU.Markets stock price, segment price, and overall market index valuation
The company's share price Liquidia Corporation
Liquidia's stock price reflects its battle to bring an inhaled drug for the treatment of pulmonary arterial hypertension to market. Its price chart reflects patent disputes with a competitor and pending regulatory decisions.
Share prices of companies in the market segment - Pharma other
Liquidia is a biopharmaceutical company specializing in the treatment of pulmonary arterial hypertension. We classify it in the Pharma Other sector, and the chart below shows the general dynamics of biotech companies, where value is determined by clinical trial results and patent disputes.
Broad Market Index - GURU.Markets
Liquidia is a biopharmaceutical company using its PRINT technology to create inhaled medications for the treatment of pulmonary hypertension. Its innovative approach makes it a key component of the GURU.Markets index. The chart below represents the entire market. Find out how Liquidia compares to it.
Change in the price of a company, segment, and market as a whole per day
LQDA - Daily change in the company's share price Liquidia Corporation
Shares of Liquidia, a biopharmaceutical company, exhibit high volatility. Change_co measures the market reaction to news about patent disputes and regulatory decisions related to its key drug. This metric is an important component of System.GURU.Markets' formulas assessing legal risks in the pharmaceutical industry.
Daily change in the price of a set of shares in a market segment - Pharma other
Liquidia Corporation is a biopharmaceutical company. This chart demonstrates the extreme volatility of the sector. Comparison with LQDA, which focuses on rare disease treatments, helps to assess it as a high-risk, clinical-data-driven asset.
Daily change in the price of a broad market stock, index - GURU.Markets
Liquidia is a biopharmaceutical company specializing in the treatment of pulmonary arterial hypertension. Biotechnology is a volatile sector. The chart below shows average daily fluctuations in this sector, providing context for analyzing Liquidia's stock performance.
Dynamics of market capitalization of the company, segment and the market as a whole over 12 months
Annual dynamics of the company's market capitalization Liquidia Corporation
Liquidia is a biopharmaceutical company developing new drugs. Its shares, like many in the sector, are volatile and react to news about clinical trials. These science-driven movements are part of the overall stock market landscape.
Annual dynamics of market capitalization of the market segment - Pharma other
Liquidia Corporation is a biopharmaceutical company specializing in the treatment of pulmonary arterial hypertension. Its innovative drug delivery technology is its key advantage. The chart below shows how its approval race and competition in this niche are impacting its volatile performance.
Annual dynamics of market capitalization of broad market stocks, index - GURU.Markets
Liquidia is a biopharmaceutical company whose stock performance is determined by the success of its drug sales and, more importantly, the outcome of patent disputes. The company's business is not dependent on economic cycles. This chart reflects events in the worlds of biotechnology and law, not macroeconomic data.
Dynamics of market capitalization of the company, segment and the market as a whole for the month
Monthly dynamics of the company's market capitalization Liquidia Corporation
Liquidia, a biopharmaceutical company specializing in the treatment of pulmonary hypertension, has sharp monthly fluctuations reflecting news about its patent disputes with competitors and regulatory decisions that will determine the future of its lead drug.
Monthly dynamics of market capitalization of the market segment - Pharma other
The biopharmaceutical sector is a high-risk, high-hope environment, where news of clinical trials can dramatically change company valuations. The dynamics of this segment, shown in the chart, illustrate its volatility. This is the context in which developers like Liquidia Corporation are pursuing their goals.
Monthly dynamics of market capitalization of broad market stocks, index - GURU.Markets
Liquidia Corporation is a biopharmaceutical company whose fate depends on the outcome of patent disputes and the approval of its drug. Its stock price is completely uncorrelated with the market and can change by tens of percent in a single day based on legal or regulatory news.
Dynamics of market capitalization of the company, segment and the market as a whole for the week
Weekly dynamics of the company's market capitalization Liquidia Corporation
Liquidia Corporation is a biopharmaceutical company focused on the treatment of pulmonary arterial hypertension. Its weekly stock price is heavily dependent on news related to patent disputes with United Therapeutics and FDA decisions that will determine the fate of its key drug.
Weekly dynamics of market capitalization of the market segment - Pharma other
Liquidia, as a biotech company whose fate hinges on the outcome of a patent dispute, is driven solely by legal news. Its dynamics are completely disconnected from the pharmaceutical sector. The chart clearly demonstrates these sharp, non-market fluctuations, driven by court decisions rather than scientific data.
Weekly dynamics of market capitalization of stocks of the broad market, index - GURU.Markets
Liquidia develops inhalation medications. Its fate depends on the outcome of a patent dispute with United Therapeutics. This is a classic biotech case, where a legal decision, not the market, determines the stock's performance. The chart clearly illustrates this binary risk.
Market capitalization of the company, segment and market as a whole
LQDA - Market capitalization of the company Liquidia Corporation
Liquidia Corporation's market capitalization dynamics are a chart of a biotech company whose fate hinges on the outcome of patent disputes. Its valuation reflects the potential of its drug for treating pulmonary arterial hypertension. Sharp fluctuations on the chart reflect investors' reactions to any news from the courtroom, which could either open or close a multi-billion-dollar market for the company.
LQDA - Share of the company's market capitalization Liquidia Corporation within the market segment - Pharma other
Liquidia Corporation is seeking to capture market share in pulmonary arterial hypertension treatment with its innovative inhaled drug delivery technology. Its market capitalization reflects its competitiveness with the market leader and the potential of its more patient-friendly product.
Market capitalization of the market segment - Pharma other
The chart below shows the pharmaceutical sector's market capitalization, and Liquidia is an interesting player focused on treating pulmonary arterial hypertension. The company uses its unique PRINT technology to create inhaled medications. Its market battle with United Therapeutics is a classic David and Goliath story in the biotech world.
Market capitalization of all companies included in a broad market index - GURU.Markets
Liquidia uses unique PRINT technology to develop inhaled drugs. Its market cap is based on the potential of this platform to create new treatments for pulmonary hypertension. The chart below shows the weighting of biotech companies with innovative drug delivery platforms.
Book value capitalization of the company, segment and market as a whole
LQDA - Book value capitalization of the company Liquidia Corporation
Liquidia's foundation is its intellectual property, PRINT, which enables the creation of highly precise inhaled drugs, and its lead candidate, YUTREPIA. The chart tells the story of a biotech company whose book value is directly dependent on success in clinical trials and patent disputes.
LQDA - Share of the company's book capitalization Liquidia Corporation within the market segment - Pharma other
Liquidia Corporation develops new drug delivery methods. The chart shows its share of real assets. These include its laboratories and manufacturing facilities, where unique PRINT technology is used to create particles for more effective therapeutics.
Market segment balance sheet capitalization - Pharma other
Liquidia Corporation is a biopharmaceutical company, but with a technology focus, making it less capital-intensive. Its PRINT technology allows for the creation of drug particles, but the manufacturing itself can be outsourced. Compared to the pharmaceutical sector, its model is more streamlined than that of giants with their own factories.
Book value of all companies included in the broad market index - GURU.Markets
Liquidia's assets are not drugs, but a unique technology for creating inhaled medications that could transform the treatment of pulmonary hypertension. The company's balance sheet reflects the value of its intellectual property and manufacturing processes. The chart shows the capital invested in this innovative drug delivery platform.
The ratio of market capitalization to book capitalization of a company, segment, and the market as a whole
Market capitalization to book capitalization ratio - Liquidia Corporation
Liquidia Corporation develops new drug delivery methods, particularly for the treatment of pulmonary hypertension. Its market value is based on its intellectual property and the potential of its technology, rather than its tangible assets. The chart shows how investors assess its chances in patent disputes and the prospects of its drugs.
Market to book capitalization ratio in a market segment - Pharma other
Liquidia Corporation develops inhalation medications. Its market capitalization is based on expectations for one key product. This chart illustrates a classic biotech scenario: a market valuation, driven by hopes for regulatory approval, bears almost no relation to the current book value of its assets.
Market to book capitalization ratio for the market as a whole
Liquidia Corporation is a biopharmaceutical company specializing in the treatment of pulmonary hypertension. Its market capitalization is based on the potential of its key drug and its delivery technology. This chart clearly illustrates how, in biotech, market valuations can exceed book value multiples, reflecting investors' bets on a future blockbuster.
Debts of the company, segment and market as a whole
LQDA - Company debts Liquidia Corporation
Liquidia Corporation is a biopharmaceutical company focused on the treatment of pulmonary hypertension. Its strategy includes using innovative technology to improve existing treatments. Debt financing is critical to conducting clinical trials and bringing a life-changing product to market.
Market segment debts - Pharma other
Liquidia Corporation is a biopharmaceutical company focused on the treatment of pulmonary hypertension. Following FDA approval, its funding needs shift from research to marketing and manufacturing. This chart shows how the company is using capital to commercialize its product and compete with existing drugs.
Market debt in general
Debt to book value of the company, segment and market as a whole
The company's debt to book capitalization ratio Liquidia Corporation
Liquidia is a biopharmaceutical company developing drugs to treat pulmonary arterial hypertension. This chart shows its financial structure amidst patent litigation. The debt and equity levels here reflect its strategy for funding legal costs and preparing for the potential launch of its product in a competitive market.
Market segment debt to market segment book capitalization - Pharma other
Liquidia Corporation is a biopharmaceutical company working on the treatment of pulmonary hypertension. The chart illustrates the debt burden in a sector where bringing a new drug to market requires significant investment. It provides insight into how Liquidia's fundraising strategy compares to the risks and potential of its key developments.
Debt to book value of all companies in the market
Liquidia Corporation, as a biotech company, relies on research funding. The chart illustrates the overall debt burden across the economy. It emphasizes that for companies like Liquidia, the overall debt level in the market is not as important as the availability of venture capital and investors' faith in their research.
P/E of the company, segment and market as a whole
P/E - Liquidia Corporation
This chart for Liquidia Corporation, a biopharmaceutical company, assesses its competition in the pulmonary hypertension treatment market. The price-to-earnings ratio reflects investor expectations regarding the outcome of patent disputes and the approval of its drug. The ratio's dynamics reflect the legal and regulatory news that impact the company's future.
P/E of the market segment - Pharma other
This chart reflects the average valuation for the biopharmaceutical sector—a benchmark for Liquidia. Comparing the valuation of this company, whose fate hinges on the outcome of patent disputes, with the industry average helps understand the level of risk the market is pricing into its shares. A valuation below the average may indicate investor skepticism about the legal outlook.
P/E of the market as a whole
Liquidia Corporation develops inhaled drugs for the treatment of rare diseases such as pulmonary arterial hypertension. Its valuation depends on the outcome of patent disputes and regulatory approval. This chart of overall risk appetite in the biotech sector shows how willing investors are to tolerate high uncertainty. In times of fear, shares of such companies can be highly volatile.
Future P/E of the company, segment and market as a whole
Future (projected) P/E of the company Liquidia Corporation
Liquidia Corporation is a biopharmaceutical company developing drugs for the treatment of pulmonary arterial hypertension. Its future depends on the outcome of patent disputes and the approval of its lead product. This chart reflects analyst expectations regarding legal victories and the drug's commercial potential, which directly impacts profit forecasts.
%20P%2FE%20Liquidia%20Corporation&width=1500&height=450&colorIndex=35&filename=GURU_Markets_-_Chart-of-the-companys-future-projected-PE-Liquidia-Corporation&v=1772513865108 "Chart of the company's future (projected) P/E Liquidia Corporation")
Future (projected) P/E of the market segment - Pharma other
Liquidia Corporation is a biopharmaceutical company developing treatments for pulmonary hypertension. Its valuation relative to other players in this therapeutic area reflects the market's opinion of the potential of its drugs and inhalation delivery technology. This demonstrates whether investors believe in its ability to compete with existing treatments.
%20P%2FE%20graph%20of%20the%20market%20segment%20-%20Pharma%20other&width=1500&height=450&colorIndex=36&filename=GURU_Markets_-_Future-projected-PE-graph-of-the-market-segment-Pharma-other&v=1772513865154 "Future (projected) P/E graph of the market segment - Pharma other")
Future (projected) P/E of the market as a whole
Liquidia Corporation is a biopharmaceutical company developing drugs for the treatment of pulmonary arterial hypertension. Its future depends on the outcome of patent disputes and regulatory approvals. This chart shows the overall risk appetite of investors. For biotechs with a binary outcome (success or failure), market optimism is a significant driver of share price support.
%20P%2FE%20of%20the%20market%20as%20a%20whole&width=1500&height=450&colorIndex=37&filename=GURU_Markets_-_Chart-of-the-future-projected-PE-of-the-market-as-a-whole&v=1772513865185 "Chart of the future (projected) P/E of the market as a whole")
Profit of the company, segment and market as a whole
Company profit Liquidia Corporation
Liquidia Corporation is a biopharmaceutical company focused on the treatment of pulmonary arterial hypertension. The financial performance shown here reflects its path to commercialization of its lead drug. Litigation outcomes and regulatory approvals are key factors for its future success.
Profit of companies in the market segment - Pharma other
Liquidia Corporation is a biopharmaceutical company using its proprietary PRINT technology to develop new drugs, particularly for pulmonary hypertension. This chart shows the overall profitability of pharmaceutical companies. It helps assess how favorable the environment is for small, innovative companies competing with industry giants.
Overall market profit
Liquidia Corporation is a biopharmaceutical company focused on the treatment of pulmonary arterial hypertension. Its future depends on the outcome of patent disputes and regulatory approval of its drugs. This is a unique story, with little connection to macroeconomic trends. For LQDA, the state of corporate profits in this chart is less important than court and FDA decisions.
Future (predicted) profit of the company, segment and market as a whole
Future (projected) profit of the company Liquidia Corporation
Liquidia Corporation is a biopharmaceutical company developing drugs to treat rare diseases, particularly pulmonary arterial hypertension. Its future profit forecast depends on the outcome of patent disputes and final FDA approval. This chart shows analysts' assessments of the company's chances of bringing its key product to market.
%20profit%20of%20the%20company%20Liquidia%20Corporation&width=1500&height=450&colorIndex=41&filename=GURU_Markets_-_Graph-of-future-projected-profit-of-the-company-Liquidia-Corporation&v=1772513865307 "Graph of future (projected) profit of the company Liquidia Corporation")
Future (predicted) profit of companies in the market segment - Pharma other
Liquidia Corporation is a biopharmaceutical company using its proprietary PRINT technology to develop inhaled medications. Their key product is aimed at treating pulmonary arterial hypertension. This chart shows forecasts for this segment. It provides investors with context for assessing the potential of Liquidia's technology to create more effective drugs and gain market share.
%20profits%20of%20companies%20in%20a%20market%20segment%20-%20Pharma%20other&width=1500&height=450&colorIndex=42&filename=GURU_Markets_-_Graph-of-future-predicted-profits-of-companies-in-a-market-segment-Pharma-other&v=1772513865346 "Graph of future (predicted) profits of companies in a market segment - Pharma other")
Future (predicted) profit of the market as a whole
Liquidia Corporation is a biopharmaceutical company specializing in the treatment of pulmonary hypertension. The overall economic environment, reflected in this earnings forecast, impacts capital availability. Market optimism facilitates raising capital for clinical trials and the commercialization of new formulations, which is the core of Liquidia's strategy.
%20profits%20of%20the%20market%20as%20a%20whole&width=1500&height=450&colorIndex=43&filename=GURU_Markets_-_Chart-of-future-predicted-profits-of-the-market-as-a-whole&v=1772513865351 "Chart of future (predicted) profits of the market as a whole")
P/S of the company, segment and market as a whole
P/S - Liquidia Corporation
Liquidia Corporation is a biopharmaceutical company developing drugs for the treatment of pulmonary hypertension. This metric reflects investors' assessment of the potential revenue from its products, which could compete with existing medications, offering new options for patients.
P/S market segment - Pharma other
Liquidia Corporation is a biopharmaceutical company using its PRINT technology to develop inhaled drugs. This chart shows the average valuation in the pharmaceutical sector. It reflects investor expectations for Liquidia's innovative platform and its potential to improve drug delivery for the treatment of pulmonary hypertension.
P/S of the market as a whole
Liquidia Corporation is a biopharmaceutical company using its proprietary PRINT technology to develop inhaled drugs. Its primary focus is the treatment of pulmonary arterial hypertension. Future revenue is dependent on regulatory approval. This chart provides a general overview of how the market values biotech companies in the development stage.
Future P/S of the company, segment and market as a whole
Future (projected) P/S of the company Liquidia Corporation
Liquidia Corporation is a biopharmaceutical company using its PRINT technology to develop inhaled drugs. Its future revenue depends on the approval and launch of a drug for the treatment of pulmonary arterial hypertension. The chart shows the market's assessment of this product's commercial potential and its ability to compete in the market.
%20P%2FS%20Liquidia%20Corporation&width=1500&height=450&colorIndex=47&filename=GURU_Markets_-_The-graph-of-the-companys-future-projected-PS-Liquidia-Corporation&v=1772513865515 "The graph of the company's future (projected) P/S Liquidia Corporation")
Future (projected) P/S of the market segment - Pharma other
Liquidia Corporation is a biopharmaceutical company developing inhaled medications for the treatment of pulmonary arterial hypertension. Its technology enables the creation of drugs with improved delivery. This chart shows how the market assesses the commercial potential of its developments compared to other pharmaceutical companies in this field.
%20P%2FS%20market%20segment%20graph%20-%20Pharma%20other&width=1500&height=450&colorIndex=48&filename=GURU_Markets_-_Future-projected-PS-market-segment-graph-Pharma-other&v=1772513865542 "Future (projected) P/S market segment graph - Pharma other")
Future (projected) P/S of the market as a whole
This indicator reflects the market's faith in biotech companies. For Liquidia, which develops inhaled drugs for rare diseases such as pulmonary arterial hypertension, it reflects the investment climate. Investor optimism allows it to raise capital to complete clinical trials and bring life-saving drugs to market.
%20P%2FS%20of%20the%20market%20as%20a%20whole&width=1500&height=450&colorIndex=49&filename=GURU_Markets_-_Chart-of-the-future-projected-PS-of-the-market-as-a-whole&v=1772513865573 "Chart of the future (projected) P/S of the market as a whole")
Sales of the company, segment and market as a whole
Company sales Liquidia Corporation
Liquidia Corporation is a biopharmaceutical company focused on the development and commercialization of drugs for the treatment of pulmonary arterial hypertension. This chart will reflect revenue from sales of its innovative inhaled drugs. Sales growth will demonstrate how successfully the company competes in the market and offers patients new therapeutic options.
Sales of companies in the market segment - Pharma other
Liquidia Corporation is a biopharmaceutical company using its PRINT technology to develop inhaled drugs. This chart shows the market size it serves. The company is focused on treating pulmonary arterial hypertension, and its innovative approach to drug delivery has the potential to change the standard of care in this field.
Overall market sales
Liquidia Corporation is a biopharmaceutical company specializing in the treatment of pulmonary hypertension. Its market capitalization and future revenue depend on the success of its drugs. The overall economic environment, shown in this chart, influences investor sentiment and the availability of funding for biotech companies in the development and commercialization stages.
Future sales volume of the company, segment and market as a whole
Future (projected) sales of the company Liquidia Corporation
Liquidia Corporation is a biopharmaceutical company specializing in the treatment of pulmonary arterial hypertension. Its core technology enables the delivery of drugs in dry powder form. This schedule reflects analyst expectations for the approval and commercial success of its lead drug, as well as its ability to compete with existing treatments.
%20sales%20of%20the%20company%20Liquidia%20Corporation&width=1500&height=450&colorIndex=53&filename=GURU_Markets_-_Schedule-of-future-projected-sales-of-the-company-Liquidia-Corporation&v=1772513865672 "Schedule of future (projected) sales of the company Liquidia Corporation")
Future (projected) sales of companies in the market segment - Pharma other
Liquidia Corporation is a biopharmaceutical company using its PRINT technology to develop inhaled drugs. This forecast reflects expectations for the pharmaceutical sector. It helps understand general trends in the development of new dosage forms and the growth potential for companies offering innovative drug delivery methods.
%20sales%20of%20companies%20in%20the%20market%20segment%20-%20Pharma%20other&width=1500&height=450&colorIndex=54&filename=GURU_Markets_-_Schedule-of-future-projected-sales-of-companies-in-the-market-segment-Pharma-other&v=1772513865689 "Schedule of future (projected) sales of companies in the market segment - Pharma other")
Future (projected) sales of the market as a whole
Liquidia Corporation is a biopharmaceutical company focused on the development and commercialization of drugs for the treatment of pulmonary hypertension. Its success depends on regulatory approval and market acceptance of its innovative drugs. This graph, reflecting the overall economic situation, influences the investment climate in biotech and future pricing policies in the healthcare sector.
%20sales%20of%20the%20market%20as%20a%20whole&width=1500&height=450&colorIndex=55&filename=GURU_Markets_-_Schedule-of-future-predicted-sales-of-the-market-as-a-whole&v=1772513865690 "Schedule of future (predicted) sales of the market as a whole")
Marginality of the company, segment and market as a whole
Company marginality Liquidia Corporation
Liquidia Corporation is developing new drug delivery methods, specifically for the treatment of pulmonary hypertension. This chart shows the company's financial status at the pre-commercial stage. Negative values reflect costs associated with clinical trials and legal proceedings leading up to potential approval and marketing of the drug.
Market segment marginality - Pharma other
Liquidia Corporation is a biopharmaceutical company using its PRINT technology to develop inhaled drugs. Its success depends on regulatory approval and commercial launch of its products. This chart helps evaluate Liquidia's operating model and development cost structure compared to other pharmaceutical companies.
Market marginality as a whole
Liquidia Corporation is a biopharmaceutical company focused on the treatment of pulmonary arterial hypertension. This overall profitability curve is not directly relevant to the company. Its future profitability depends on the success of drug development and commercialization, as well as its ability to compete with existing treatments in this narrow therapeutic area.
Employees in the company, segment and market as a whole
Number of employees in the company Liquidia Corporation
Liquidia Corporation is a biopharmaceutical company using its PRINT technology to develop inhaled medications. This chart shows the company's research and manufacturing teams. The growth in staff is directly related to progress in clinical trials and preparation for commercial production of its drugs.
Share of the company's employees Liquidia Corporation within the market segment - Pharma other
Liquidia Corporation uses unique PRINT technology to create inhaled medications. In this innovative field, the team is a key asset. This metric reflects the percentage of scientists and engineers specializing in the development of drug particles and delivery systems that the company employs, demonstrating its concentration of unique competencies in the pharmaceutical industry.
Number of employees in the market segment - Pharma other
Liquidia Corporation is a biopharmaceutical company using its proprietary PRINT technology to develop inhaled drugs for rare diseases, particularly pulmonary arterial hypertension. This chart reflects employment in innovative pharmaceuticals, showing how the development of new drug delivery systems for orphan diseases is creating new, science-intensive jobs.
Number of employees in the market as a whole
Liquidia Corporation is a biopharmaceutical company working on the treatment of pulmonary hypertension. Their activities fall into a knowledge-intensive sector, where employment is determined by multi-year research and development cycles. The growth of such companies does not create massive jobs, but it does create a scientific elite that will ensure the country's future technological leadership.
Market capitalization per employee (in thousands of dollars) of the company, segment, and market as a whole
Market capitalization per employee (in thousands of dollars) of the company Liquidia Corporation (LQDA)
Liquidia is a biopharmaceutical company using unique technology to create inhaled medications. This chart shows how the market values innovations in drug delivery. Its high market capitalization per employee reflects the value of its PRINT technology platform and its potential application across a variety of diseases.
%20of%20the%20company%20Liquidia%20Corporation%20(LQDA)&width=1500&height=450&colorIndex=63&filename=GURU_Markets_-_Chart-of-market-capitalization-per-employee-in-thousands-of-dollars-of-the-company-Liquidia-Corporation-LQDA&v=1772513865881 "Chart of market capitalization per employee (in thousands of dollars) of the company Liquidia Corporation (LQDA)")
Market capitalization per employee (in thousands of dollars) in the market segment - Pharma other
Liquidia (LQDA) is a biopharmaceutical company using its proprietary PRINT technology to develop inhaled drugs, specifically for the treatment of pulmonary arterial hypertension (PAH). This chart shows the average market capitalization per employee in the sector. It helps assess how the market views their technology platform and the potential of their PAH treatment based on their small workforce.
%20by%20market%20segment%20-%20Pharma%20other&width=1500&height=450&colorIndex=64&filename=GURU_Markets_-_Market-capitalization-per-employee-in-thousands-of-dollars-by-market-segment-Pharma-other&v=1772513865912 "Market capitalization per employee (in thousands of dollars) by market segment - Pharma other")
Market capitalization per employee (in thousands of dollars) for the overall market
Liquidia Corporation is a biopharmaceutical company specializing in the development of treatments for pulmonary hypertension. This chart shows the average market value generated by one specialist, highlighting how the market evaluates the potential of new drugs and scientific developments.
%20for%20the%20overall%20market&width=1500&height=450&colorIndex=65&filename=GURU_Markets_-_Market-capitalization-per-employee-in-thousands-of-dollars-for-the-overall-market&v=1772513865928 "Market capitalization per employee (in thousands of dollars) for the overall market")
Profit per employee (in thousands of dollars) for the company, segment, and market as a whole
Profit per employee (in thousands of dollars) of the company Liquidia Corporation (LQDA)
Liquidia is a biopharmaceutical company using PRINT technology to develop new drugs (primarily for pulmonary hypertension). This graph shows the loss per employee during the R&D phase. It reflects how much the company invests in its research staff to bring a product to market, where it has the potential to generate high profits.
%20Chart%20Liquidia%20Corporation%20(LQDA)&width=1500&height=450&colorIndex=66&filename=GURU_Markets_-_Company-Profit-Per-Employee-in-thousands-of-dollars-Chart-Liquidia-Corporation-LQDA&v=1772513865972 "Company Profit Per Employee (in thousands of dollars) Chart Liquidia Corporation (LQDA)")
Profit per employee (in thousands of dollars) in the market segment - Pharma other
Liquidia (LQDA) is an R&D biotech (treating pulmonary hypertension). This chart shows the benchmark for "Pharma" (R&D). The average profit per employee in this sector (venture R&D) is *negative*. This benchmark reflects the "burning" of money in the hopes of one or two mega-successes. The entire sector is an R&D race, spending billions on elite scientists.
%20in%20the%20market%20segment%20-%20Pharma%20other&width=1500&height=450&colorIndex=67&filename=GURU_Markets_-_Chart-of-profit-per-employee-in-thousands-of-dollars-in-the-market-segment-Pharma-other&v=1772513866072 "Chart of profit per employee (in thousands of dollars) in the market segment - Pharma other")
Profit per employee (in thousands of dollars) for the market as a whole
Liquidia Corporation is a biopharmaceutical company using PRINT technology to create new drug formulations (for example, for pulmonary hypertension). It is an R&D company awaiting approval of a key drug. This chart likely shows the company's burn rate, but investors are watching it in anticipation of a commercial launch, which should dramatically change that.
%20for%20the%20market%20as%20a%20whole&width=1500&height=450&colorIndex=68&filename=GURU_Markets_-_Chart-of-profit-per-employee-in-thousands-of-dollars-for-the-market-as-a-whole&v=1772513866157 "Chart of profit per employee (in thousands of dollars) for the market as a whole")
Sales to employees of the company, segment and market as a whole
Sales per company employee Liquidia Corporation (LQDA)
Liquidia Corporation is a biopharmaceutical company specializing in the treatment of pulmonary hypertension. This graph shows the critical transition point from research to sales. For biotech, growth in this indicator is a sign of successful commercialization, when a product begins to generate revenue, justifying years of development.
&width=1500&height=450&colorIndex=69&filename=GURU_Markets_-_Sales-chart-per-company-employee-Liquidia-Corporation-LQDA&v=1772513866230 "Sales chart per company employee Liquidia Corporation (LQDA)")
Sales per employee in the market segment - Pharma other
Liquidia Corporation is a biopharmaceutical company using its PRINT technology to develop inhaled drugs, particularly for pulmonary hypertension. This chart shows the average revenue per employee in this segment. It helps assess how productive Liquidia's team is in commercializing its developments compared to its competitors.
Sales per employee for the market as a whole
Liquidia Corporation is a biopharmaceutical company focused on the treatment of pulmonary hypertension. The company is in the final stages of obtaining approval for its lead drug. This metric is not yet relevant, as there is no commercial revenue. However, it will become key after launch, demonstrating the effectiveness of their future commercial team.
Short shares by company, segment and market as a whole
Shares shorted by company Liquidia Corporation (LQDA)
Liquidia Corporation is developing an inhaled formulation of a drug for the treatment of pulmonary hypertension. The company is engaged in a fierce patent war with United Therapeutics, which dominates the market. This chart shows the volume of bets by "bears" who don't believe Liquidia will win the lawsuits and bring its drug to market.
&width=1500&height=450&colorIndex=72&filename=GURU_Markets_-_Short-Shares-Chart-for-the-Company-Liquidia-Corporation-LQDA&v=1772513866373 "Short Shares Chart for the Company Liquidia Corporation (LQDA)")
Shares shorted by market segment - Pharma other
Liquidia Corporation is a biopharmaceutical company using its PRINT technology to develop inhaled drugs, particularly for the treatment of pulmonary arterial hypertension. This chart shows the overall short position in the biotech sector. Its rise signals investor doubts about clinical success, FDA approval, or the patent disputes that characterize this risky industry.
Shares shorted by the overall market
Liquidia (LQDA) is a biotech focused on pulmonary hypertension. This indicator (`Short_All`) is a mirror of market fear. When it rises, investors panic and shed risk. Biotech stocks, even those with promising prospects, often suffer a sell-off when general pessimism rules the market.
RSI 14 indicator for a company, segment, and market as a whole
The company's RSI 14 indicator Liquidia Corporation (LQDA)
Liquidia (LQDA) is a biopharmaceutical company focused on the treatment of pulmonary arterial hypertension (PAH). They use their PRINT technology to create inhaled medications. Their fate is closely tied to patent disputes. This chart measures hype. It shows "overheated" (above 70) on positive court decisions or "oversold" (below 30) on news of delays.
&width=1500&height=450&colorIndex=75&filename=GURU_Markets_-_RSI-14-indicator-chart-for-the-companys-stock-Liquidia-Corporation-LQDA&v=1772513866516 "RSI 14 indicator chart for the company's stock Liquidia Corporation (LQDA)")
RSI 14 Market Segment - Pharma other
Liquidia (LQDA) is a biopharmaceutical company using its PRINT technology to create inhaled medications, specifically for the treatment of pulmonary arterial hypertension. This chart tracks overall sentiment in the Pharmaceuticals sector. It helps investors understand whether LQDA's performance reflects its patent litigation and developments, or whether the entire sector is overheated or oversold.
RSI 14 for the overall market
Liquidia (LQDA) is a biotech company. Like everything in its sector, it's critically dependent on this schedule. Market euphoria is an opportunity to easily raise hundreds of millions of dollars for research. Market panic is the risk of running out of money before its breakthrough technologies reach patients.
Analyst consensus forecast for the company's share price, the segment, and the market as a whole
Analyst consensus stock price forecast LQDA (Liquidia Corporation)
Liquidia Corporation is a biopharmaceutical company using its PRINT technology to create inhaled medications. Its lead candidate is aimed at treating pulmonary arterial hypertension. This chart represents the collective opinion of experts on the 12-month price of LQDA shares, taking into account regulatory risks.
&width=1500&height=450&colorIndex=78&filename=GURU_Markets_-_A-chart-showing-analyst-consensus-forecasts-for-the-expected-stock-price.-LQDA-Liquidia-Corporation&v=1772513866678 "A chart showing analyst consensus forecasts for the expected stock price. LQDA (Liquidia Corporation)")
The difference between the consensus estimate and the actual stock price LQDA (Liquidia Corporation)
Liquidia (LQDA) is a biopharmaceutical company developing an inhaled formulation of a drug (Yutrepia) for the treatment of pulmonary arterial hypertension (PAH). This chart shows the assessment of their patent battle. It measures the gap between the price and the consensus target, reflecting whether analysts believe they will win the case and reach the market.
&width=1500&height=450&colorIndex=79&filename=GURU_Markets_-_A-chart-showing-the-difference-between-the-consensus-forecast-and-the-actual-stock-price.-LQDA-Liquidia-Corporation&v=1772513866731 "A chart showing the difference between the consensus forecast and the actual stock price. LQDA (Liquidia Corporation)")
Analyst consensus forecast for stock prices by market segment - Pharma other
Liquidia is a biopharmaceutical company developing improved (inhaled) forms of existing drugs for the treatment of pulmonary arterial hypertension (PAH). This chart shows the overall expectations of analysts for the pharmaceutical sector. It reflects whether experts believe new delivery forms for existing drugs are competitive.
Analysts' consensus forecast for the overall market share price
Liquidia (LQDA) is a biotech developing drugs to treat pulmonary hypertension. It's a risky R&D play. This chart of overall market sentiment is important. Optimism = the market is willing to burn cash funding unprofitable biotechs with high potential. Pessimism = risk aversion, and capital for R&D dries up.
AKIMA index of the company, segment and market as a whole
AKiMA Company Index Liquidia Corporation
Liquidia is a biotech company focused on the treatment of pulmonary arterial hypertension (PAH). Their strategy is not to develop a new molecule, but to use innovative technology (PRINT) to deliver an existing drug (treprostinil) in a more convenient form. This chart is an assessment of their patent fight, reflecting their chances in court against market leader United Therapeutics.
AKIMA Market Segment Index - Pharma other
Liquidia (LQDA) is a single-product biotech targeting the pulmonary hypertension (PH) market; the company is attempting to launch its inhaled version (Yutrepia) of a key drug, challenging the leader (United Therapeutics). This summary metric measures R&D. The graph shows the segment average. This benchmark: how does Liquidia's risky bet (on a single product) differentiate it from the average pharma company?
The AKIM Index for the overall market
Liquidia is a biopharmaceutical company improving drug delivery for the treatment of pulmonary hypertension (PH). It competes with United Therapeutics. This chart, which reflects the market average, provides a macro backdrop. It helps assess how this growth story and patent disputes compare to the overall economic trends affecting biotech.
